Donor Sperm Banks & the Donor-Conceived Reckoning
The industry, genetic screening, and the end of anonymity
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Donor tissue regulated by FDA (donor eligibility/screening, 21 CFR 1271); donor selection practices largely self-regulated
Reference only. Not medical advice.
What can go wrong
Risks include undisclosed or under-tested genetic conditions transmitted across large sibling cohorts, accidental consanguinity, identity and psychological impacts on donor-conceived people, and outright fraud (physicians using their own sperm; misrepresented donor profiles). Self-reported donor health histories can be inaccurate. The absence of mandatory national limits on offspring per donor is a structural gap.
This is something to take to a clinician. The Atlas can tell you what is known about donor sperm banks & the donor-conceived reckoning in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Donor sperm banks (Cryos, California Cryobank, Seattle Sperm Bank, Fairfax, Xytex) screen, freeze, and sell donor sperm for use by single parents, same-sex couples, and male-factor couples. The FDA regulates infectious-disease screening of donor tissue, but limits on donor offspring numbers and genetic disclosure are largely industry self-policed. Consumer DNA testing (23andMe, AncestryDNA) has collapsed donor anonymity and surfaced a 'donor-conceived reckoning' over identity, sibling-pod sizes, and disclosure ethics.
A lightly-regulated marketplace meeting the era of consumer DNA tests.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Banks recruit donors, run infectious-disease and (increasingly) expanded genetic-carrier screening, quarantine and freeze samples, and sell vials with donor profiles. Quality control includes post-thaw motility standards. The genetic-screening depth, family-limit enforcement, and identity-disclosure policy vary by bank and jurisdiction - the discretionary layer the FDA does not govern.
What people get wrong
Often saidSperm donors are anonymous for life
ActuallyConsumer DNA databases have made true anonymity essentially impossible; many banks now offer open-identity donors.
Often saidBanks strictly limit how many children a donor can father
ActuallyLimits are largely voluntary and bank-specific; some donors are linked to very large sibling cohorts, and tracking relies on self-reporting.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
How we got here
Therapeutic donor insemination dates to the 19th-20th centuries under strict secrecy. Commercial cryobanks scaled from the 1970s-1980s. The 2010s consumer-genomics boom (23andMe, AncestryDNA) and an organized donor-conceived advocacy movement dismantled anonymity and forced reckonings over offspring limits, disclosure, and fraud - culminating in new state fertility-fraud statutes.
- 1970s-1980sCommercial sperm cryobanks scale up
- 2005FDA donor-tissue screening rules take effect
- 2010sConsumer DNA testing erodes donor anonymity
- 2019-2020sFertility-fraud prosecutions and state laws; donor-conceived advocacy grows
Set against the alternatives
Compared with the tightly clinical micro-TESE/ICSI pathway, donor sperm is a consumer-facing marketplace with marketing, catalogs, and tiered pricing (open-ID donors, 'staff favorites,' celebrity-lookalike framing). Genetic-screening breadth and disclosure policy - not freezing technology - are the real differentiators between banks.
What we do not know
- Should national limits on offspring per donor be mandatory and enforced?
- How should donor-conceived people's right to genetic and identity information be guaranteed?
- Can the industry standardize expanded carrier screening and accurate donor disclosure?
At a glance
- FDA scope
- mandates infectious-disease donor screening, not offspring caps
- Anonymity
- effectively ended by consumer DNA databases
- Sibling pods
- some donors linked to dozens-to-hundreds of offspring
- Notable cases
- fraud/misrepresentation (e.g., the Donald Cline 'fertility fraud' physician case)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Donor Sperm Banks & the Donor-Conceived Reckoning. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
FDA donor-tissue rules (21 CFR Part 1271)2005
Established mandatory donor eligibility/infectious-disease screening for reproductive tissue
Donor-conceived community surveys and reports2010s-2020s
Documented desire for identity access, concerns over large sibling groups, and support for ending anonymity
Fertility-fraud prosecutions and legislation2019-2020s
Cases like Donald Cline spurred state 'fertility fraud' laws criminalizing deceptive insemination